Durvalumab +/- Tremelimumab Plus Platinum-Etoposide In First-Line Extensive-Stage Sclc (Es-Sclc): 3-Year Overall Survival Update From The Phase Iii Caspian Study L. Paz-Ares,Y. Chen,N. Reinmuth, K. Hotta,D. Trukhin, G. Statsenko,M. J. Hochmair,M. Ozguroglu, J. H. Ji, O. Voitko,A. Poltoratskiy,F. Verderame, L. Havel,I. Bondarenko, G. Losonczy, N. V. Conev, H. L. Broadhurst, T. Dalvi,H. Jiang, J. W. GoldmanANNALS OF ONCOLOGY（2021）引用 10|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
